JP2010534647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534647A5 JP2010534647A5 JP2010517536A JP2010517536A JP2010534647A5 JP 2010534647 A5 JP2010534647 A5 JP 2010534647A5 JP 2010517536 A JP2010517536 A JP 2010517536A JP 2010517536 A JP2010517536 A JP 2010517536A JP 2010534647 A5 JP2010534647 A5 JP 2010534647A5
- Authority
- JP
- Japan
- Prior art keywords
- thiazole
- methyl
- azabicyclo
- ylmethyl
- octane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001424 substituent group Chemical group 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- -1 imidazo [2,1-b] thiazolyl Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000597 dioxinyl group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- CHDSHBWEGSCEDX-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1CCO2 CHDSHBWEGSCEDX-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 229910052801 chlorine Chemical group 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000035622 drinking Effects 0.000 claims 1
- 230000007937 eating Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Chemical group 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- MHVSOGIDKPXDDB-ONTIZHBOSA-N n-[[(2s,3as,6as)-1-(2-cyclopropyl-5-phenyl-1,3-thiazole-4-carbonyl)-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-1,2-benzoxazole-3-carboxamide Chemical compound N1([C@H]2CCC[C@H]2C[C@H]1CNC(=O)C=1C2=CC=CC=C2ON=1)C(=O)C=1N=C(C2CC2)SC=1C1=CC=CC=C1 MHVSOGIDKPXDDB-ONTIZHBOSA-N 0.000 claims 1
- OTTMEKXDJSZAIX-HFMPRLQTSA-N n-[[(2s,3as,6as)-1-(2-cyclopropyl-5-phenyl-1,3-thiazole-4-carbonyl)-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound N1([C@H]2CCC[C@H]2C[C@H]1CNC(=O)C=1C=2CCOC=2C=CC=1)C(=O)C=1N=C(C2CC2)SC=1C1=CC=CC=C1 OTTMEKXDJSZAIX-HFMPRLQTSA-N 0.000 claims 1
- IHFMBXBZXXTVQP-JTAQYXEDSA-N n-[[(2s,3as,6as)-1-(2-methyl-5-phenyl-1,3-thiazole-4-carbonyl)-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C=3CCOC=3C=CC=2)=C1C1=CC=CC=C1 IHFMBXBZXXTVQP-JTAQYXEDSA-N 0.000 claims 1
- OJJOZHOOORWXLU-FHWLQOOXSA-N n-[[(2s,3as,6as)-1-[2-amino-5-(4-methylphenyl)-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-6-methylimidazo[2,1-b][1,3]thiazole-5-carboxamide Chemical compound N1([C@H]2CCC[C@H]2C[C@H]1CNC(=O)C=1N2C=CSC2=NC=1C)C(=O)C=1N=C(N)SC=1C1=CC=C(C)C=C1 OJJOZHOOORWXLU-FHWLQOOXSA-N 0.000 claims 1
- BYQISEBZCATOTP-JBACZVJFSA-N n-[[(2s,3as,6as)-1-[2-cyclopropyl-5-(4-fluorophenyl)-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-6-methylimidazo[2,1-b][1,3]thiazole-5-carboxamide Chemical compound N1([C@H]2CCC[C@H]2C[C@H]1CNC(=O)C=1N2C=CSC2=NC=1C)C(=O)C=1N=C(C2CC2)SC=1C1=CC=C(F)C=C1 BYQISEBZCATOTP-JBACZVJFSA-N 0.000 claims 1
- MKOOSJHWTKSGGN-YYWHXJBOSA-N n-[[(2s,3as,6as)-1-[2-cyclopropyl-5-[3-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-6-methylimidazo[2,1-b][1,3]thiazole-5-carboxamide Chemical compound N1([C@H]2CCC[C@H]2C[C@H]1CNC(=O)C=1N2C=CSC2=NC=1C)C(=O)C=1N=C(C2CC2)SC=1C1=CC=CC(C(F)(F)F)=C1 MKOOSJHWTKSGGN-YYWHXJBOSA-N 0.000 claims 1
- XKTNIQYJNLZQST-PTLVVNQVSA-N n-[[(2s,3as,6as)-1-[2-methyl-5-(3-methylphenyl)-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C=3CCOC=3C=CC=2)=C1C1=CC=CC(C)=C1 XKTNIQYJNLZQST-PTLVVNQVSA-N 0.000 claims 1
- SLOBLIQJUATOMS-ONTIZHBOSA-N n-[[(2s,3as,6as)-1-[2-methyl-5-(4-methylphenyl)-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-1,2-benzoxazole-3-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C3=CC=CC=C3ON=2)=C1C1=CC=C(C)C=C1 SLOBLIQJUATOMS-ONTIZHBOSA-N 0.000 claims 1
- IEPRJAMZQWKVIP-ACRUOGEOSA-N n-[[(2s,3as,6as)-1-[2-methyl-5-(4-methylphenyl)-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-6-methylimidazo[2,1-b][1,3]thiazole-5-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2N3C=CSC3=NC=2C)=C1C1=CC=C(C)C=C1 IEPRJAMZQWKVIP-ACRUOGEOSA-N 0.000 claims 1
- UOGOAQDNTHKHQE-NYDSKATKSA-N n-[[(2s,3as,6as)-1-[2-methyl-5-[3-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C=3CCOC=3C=CC=2)=C1C1=CC=CC(C(F)(F)F)=C1 UOGOAQDNTHKHQE-NYDSKATKSA-N 0.000 claims 1
- NLZYZGYKMSDBCX-CEXJFXJFSA-N n-[[(2s,3as,6as)-1-[5-(3,4-dichlorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C=3CCOC=3C=CC=2)=C1C1=CC=C(Cl)C(Cl)=C1 NLZYZGYKMSDBCX-CEXJFXJFSA-N 0.000 claims 1
- XMHDECCCYKDFFL-CEXJFXJFSA-N n-[[(2s,3as,6as)-1-[5-(3,4-difluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C=3CCOC=3C=CC=2)=C1C1=CC=C(F)C(F)=C1 XMHDECCCYKDFFL-CEXJFXJFSA-N 0.000 claims 1
- RVNJNVQNALAQCV-XTJBDQBJSA-N n-[[(2s,3as,6as)-1-[5-(3,4-dimethylphenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C=3CCOC=3C=CC=2)=C1C1=CC=C(C)C(C)=C1 RVNJNVQNALAQCV-XTJBDQBJSA-N 0.000 claims 1
- VVVNENZVTHCPBD-XTJBDQBJSA-N n-[[(2s,3as,6as)-1-[5-(3,5-dimethylphenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C=3CCOC=3C=CC=2)=C1C1=CC(C)=CC(C)=C1 VVVNENZVTHCPBD-XTJBDQBJSA-N 0.000 claims 1
- AAKPRGKQSXOYMF-JTJYXVOQSA-N n-[[(2s,3as,6as)-1-[5-(3-acetamidophenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound CC(=O)NC1=CC=CC(C2=C(N=C(C)S2)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C=3CCOC=3C=CC=2)=C1 AAKPRGKQSXOYMF-JTJYXVOQSA-N 0.000 claims 1
- WSKYKBBQUQDPAU-CEXJFXJFSA-N n-[[(2s,3as,6as)-1-[5-(3-bromo-4-fluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C=3CCOC=3C=CC=2)=C1C1=CC=C(F)C(Br)=C1 WSKYKBBQUQDPAU-CEXJFXJFSA-N 0.000 claims 1
- DOTCHYMEKCDVKK-LRQRDZAKSA-N n-[[(2s,3as,6as)-1-[5-(3-chlorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-1,2-benzoxazole-3-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C3=CC=CC=C3ON=2)=C1C1=CC=CC(Cl)=C1 DOTCHYMEKCDVKK-LRQRDZAKSA-N 0.000 claims 1
- COJJWPSZHRAIPC-NYDSKATKSA-N n-[[(2s,3as,6as)-1-[5-(3-chlorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C=3CCOC=3C=CC=2)=C1C1=CC=CC(Cl)=C1 COJJWPSZHRAIPC-NYDSKATKSA-N 0.000 claims 1
- TYJSGGWMHHXTRT-VDGAXYAQSA-N n-[[(2s,3as,6as)-1-[5-(3-chlorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-6-methylimidazo[2,1-b][1,3]thiazole-5-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2N3C=CSC3=NC=2C)=C1C1=CC=CC(Cl)=C1 TYJSGGWMHHXTRT-VDGAXYAQSA-N 0.000 claims 1
- GBOFRAOTAREROM-LRQRDZAKSA-N n-[[(2s,3as,6as)-1-[5-(3-fluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-1,2-benzoxazole-3-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C3=CC=CC=C3ON=2)=C1C1=CC=CC(F)=C1 GBOFRAOTAREROM-LRQRDZAKSA-N 0.000 claims 1
- KCNYWMNZHUVRLE-NYDSKATKSA-N n-[[(2s,3as,6as)-1-[5-(3-fluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C=3CCOC=3C=CC=2)=C1C1=CC=CC(F)=C1 KCNYWMNZHUVRLE-NYDSKATKSA-N 0.000 claims 1
- UWZLSALRXPTWMD-VDGAXYAQSA-N n-[[(2s,3as,6as)-1-[5-(3-fluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-6-methylimidazo[2,1-b][1,3]thiazole-5-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2N3C=CSC3=NC=2C)=C1C1=CC=CC(F)=C1 UWZLSALRXPTWMD-VDGAXYAQSA-N 0.000 claims 1
- HDSGIWRRXTZDIQ-LEDOBFOHSA-N n-[[(2s,3as,6as)-1-[5-(4-bromophenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C=3CCOC=3C=CC=2)=C1C1=CC=C(Br)C=C1 HDSGIWRRXTZDIQ-LEDOBFOHSA-N 0.000 claims 1
- JDOFJJCZRDUQQF-LEDOBFOHSA-N n-[[(2s,3as,6as)-1-[5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2C=3CCOC=3C=CC=2)=C1C1=CC=C(F)C=C1 JDOFJJCZRDUQQF-LEDOBFOHSA-N 0.000 claims 1
- WXNQUUOIXDSYPW-IHPCNDPISA-N n-[[(2s,3as,6as)-1-[5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrol-2-yl]methyl]-6-methylimidazo[2,1-b][1,3]thiazole-5-carboxamide Chemical compound S1C(C)=NC(C(=O)N2[C@H]3CCC[C@H]3C[C@H]2CNC(=O)C=2N3C=CSC3=NC=2C)=C1C1=CC=C(F)C=C1 WXNQUUOIXDSYPW-IHPCNDPISA-N 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 229940001470 psychoactive drug Drugs 0.000 claims 1
- 239000004089 psychotropic agent Substances 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2007052991 | 2007-07-27 | ||
| PCT/IB2008/052989 WO2009016564A2 (en) | 2007-07-27 | 2008-07-25 | 2-aza-bicyclo[3.3.0]octane derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010534647A JP2010534647A (ja) | 2010-11-11 |
| JP2010534647A5 true JP2010534647A5 (enExample) | 2011-09-01 |
Family
ID=40174799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517536A Pending JP2010534647A (ja) | 2007-07-27 | 2008-07-25 | ２−アザ−ビシクロ［３．３．０］オクタン誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8288429B2 (enExample) |
| EP (1) | EP2183246A2 (enExample) |
| JP (1) | JP2010534647A (enExample) |
| KR (1) | KR20100046047A (enExample) |
| CN (1) | CN101874028B (enExample) |
| AU (1) | AU2008281399A1 (enExample) |
| BR (1) | BRPI0814593A2 (enExample) |
| CA (1) | CA2693820A1 (enExample) |
| MA (1) | MA31593B1 (enExample) |
| NZ (1) | NZ583487A (enExample) |
| RU (1) | RU2478099C2 (enExample) |
| WO (1) | WO2009016564A2 (enExample) |
| ZA (1) | ZA201001434B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002809A1 (es) * | 2006-09-29 | 2008-04-18 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas |
| US8133901B2 (en) | 2006-12-01 | 2012-03-13 | Actelion Pharmaceuticals Ltd. | 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors |
| TW200833328A (en) * | 2006-12-28 | 2008-08-16 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.1.0]hexane derivatives |
| CL2008000836A1 (es) * | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| US8030495B2 (en) | 2007-05-23 | 2011-10-04 | Coleman Paul J | Cyclopropyl pyrrolidine orexin receptor antagonists |
| JP2010531871A (ja) * | 2007-07-03 | 2010-09-30 | アクテリオン ファーマシューティカルズ リミテッド | ３−アザ−ビシクロ［３．３．０］オクタン化合物 |
| CA2699328A1 (en) * | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
| BRPI0908096A2 (pt) * | 2008-02-21 | 2015-08-25 | Actelion Pharmaceuticals Ltd | Derivado de 2-aza-biciclo [2.2.1] heptano |
| CN102015645B (zh) * | 2008-04-30 | 2012-11-14 | 埃科特莱茵药品有限公司 | 哌啶和吡咯烷化合物 |
| WO2010044054A1 (en) * | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
| ES2585806T3 (es) | 2009-10-23 | 2016-10-10 | Janssen Pharmaceutica N.V. | Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina |
| CA2785957C (en) | 2009-12-29 | 2015-06-16 | Suven Life Sciences Limited | .alpha.4.beta.2 neuronal nicotinic acetylcholine receptor ligands |
| WO2011082268A2 (en) | 2009-12-30 | 2011-07-07 | Arqule Inc. | Substituted naphthalenyl-pyrimidine compounds |
| WO2013119639A1 (en) * | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| ITMI20120424A1 (it) | 2012-03-19 | 2013-09-20 | Rottapharm Spa | Composti chimici |
| TWI570120B (zh) | 2012-06-04 | 2017-02-11 | 艾克泰聯製藥有限公司 | 苯并咪唑脯胺酸衍生物 |
| AU2013328301A1 (en) | 2012-10-10 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
| CN105051040A (zh) | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
| JP6496733B2 (ja) | 2013-12-03 | 2019-04-03 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | （ｓ）−（２−（６−クロロ−７−メチル−１ｈ−ベンゾ［ｄ］イミダゾール−２−イル）−２−メチルピロリジン−１−イル）（５−メトキシ−２−（２ｈ−１，２，３−トリアゾール−２−イル）フェニル）メタノンの結晶形及びオレキシン受容体アンタゴニストとしてのその使用 |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| KR102330133B1 (ko) | 2013-12-04 | 2021-11-23 | 이도르시아 파마슈티컬스 리미티드 | 벤즈이미다졸-프롤린 유도체의 용도 |
| TW201613902A (en) | 2014-08-13 | 2016-04-16 | Eolas Therapeutics Inc | Difluoropyrrolidines as orexin receptor modulators |
| LT3414241T (lt) | 2016-02-12 | 2022-08-25 | Astrazeneca Ab | Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai |
| HRP20220642T1 (hr) | 2016-03-10 | 2022-06-24 | Janssen Pharmaceutica Nv | Postupci za liječenje depresije uporabom antagonista receptora oreksina 2 |
| WO2017194548A1 (en) | 2016-05-10 | 2017-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
| GB201618181D0 (en) | 2016-10-27 | 2016-12-14 | J Banks & Co Ltd | Slide turn door assembly and support mechanism therefor |
| WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
| WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
| WO2022040058A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Cyclopentapyrrole orexin receptor agonists |
| TW202400149A (zh) | 2022-05-13 | 2024-01-01 | 瑞士商愛杜西亞製藥有限公司 | 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物 |
| WO2025224168A1 (en) | 2024-04-24 | 2025-10-30 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57139032A (en) | 1981-02-20 | 1982-08-27 | Takasago Corp | 2-(butan-2-on-3-yl)-5-methylphenol and perfumery composition containing the same |
| IT1231413B (it) * | 1987-09-23 | 1991-12-04 | Angeli Inst Spa | Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht |
| DE4243287A1 (de) * | 1992-06-19 | 1993-12-23 | Basf Ag | N-Substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung |
| GB9319732D0 (en) | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| AU2381995A (en) | 1994-04-29 | 1995-11-29 | Pharmacia & Upjohn Company | Methanol derivatives for treatment of retroviral infections especially hiv infections |
| AU2001272476A1 (en) | 2000-06-16 | 2001-12-24 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
| US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| EP1353918B1 (en) | 2000-11-28 | 2005-01-12 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
| WO2002089800A2 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| CZ20032990A3 (cs) | 2001-05-05 | 2004-04-14 | Smithkline Beecham P. L. C. | N-aroylové cyklické aminy |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| WO2003002561A1 (en) | 2001-06-28 | 2003-01-09 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| WO2004026866A1 (en) | 2002-09-18 | 2004-04-01 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
| AU2003276919B2 (en) | 2002-09-25 | 2013-05-16 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| RU2417225C2 (ru) | 2004-03-25 | 2011-04-27 | Мемори Фармасьютиклз Корпорейшн | Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение |
| US20060014733A1 (en) | 2004-07-19 | 2006-01-19 | Pfizer Inc | Histamine-3 agonists and antagonists |
| CL2007002809A1 (es) | 2006-09-29 | 2008-04-18 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas |
| US8133901B2 (en) | 2006-12-01 | 2012-03-13 | Actelion Pharmaceuticals Ltd. | 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| ES2351079T3 (es) | 2007-05-14 | 2011-01-31 | Actelion Pharmaceuticals Ltd. | Derivados de 2-ciclopropil-tiazol. |
| WO2008147518A1 (en) | 2007-05-23 | 2008-12-04 | Merck & Co., Inc. | Pyridyl piperidine orexin receptor antagonists |
| US8030495B2 (en) | 2007-05-23 | 2011-10-04 | Coleman Paul J | Cyclopropyl pyrrolidine orexin receptor antagonists |
| TW200911242A (en) | 2007-07-03 | 2009-03-16 | Glaxo Group Ltd | Novel compounds |
| GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
| AR067665A1 (es) | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano |
| CA2699328A1 (en) | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
| CA2705411A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as orexin receptor antagonists |
| BRPI0908096A2 (pt) | 2008-02-21 | 2015-08-25 | Actelion Pharmaceuticals Ltd | Derivado de 2-aza-biciclo [2.2.1] heptano |
| CN102015645B (zh) | 2008-04-30 | 2012-11-14 | 埃科特莱茵药品有限公司 | 哌啶和吡咯烷化合物 |
| CA2724648A1 (en) | 2008-05-22 | 2009-11-26 | Merck Sharp & Dohme Corp. | Process for the preparation of an orexin receptor antagonist |
-
2008
- 2008-07-25 KR KR1020107004524A patent/KR20100046047A/ko not_active Withdrawn
- 2008-07-25 WO PCT/IB2008/052989 patent/WO2009016564A2/en not_active Ceased
- 2008-07-25 JP JP2010517536A patent/JP2010534647A/ja active Pending
- 2008-07-25 US US12/670,823 patent/US8288429B2/en not_active Expired - Fee Related
- 2008-07-25 RU RU2010106854/04A patent/RU2478099C2/ru not_active IP Right Cessation
- 2008-07-25 EP EP08789443A patent/EP2183246A2/en not_active Withdrawn
- 2008-07-25 NZ NZ583487A patent/NZ583487A/en not_active IP Right Cessation
- 2008-07-25 CA CA2693820A patent/CA2693820A1/en not_active Abandoned
- 2008-07-25 BR BRPI0814593-8A2A patent/BRPI0814593A2/pt not_active IP Right Cessation
- 2008-07-25 AU AU2008281399A patent/AU2008281399A1/en not_active Abandoned
- 2008-07-25 CN CN200880100389XA patent/CN101874028B/zh not_active Expired - Fee Related
-
2010
- 2010-02-05 MA MA32589A patent/MA31593B1/fr unknown
- 2010-02-26 ZA ZA2010/01434A patent/ZA201001434B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010106854A (ru) | Производные 2-аза-бицикло[3.3.0]октана | |
| RU2435757C2 (ru) | Производные 3-циклил-2-(4-сульфамоилфенил)-n-циклилпропионамида, применимые для лечения нарушенной переносимости глюкозы и диабета | |
| RU2010138640A (ru) | Производные 2-аза-бицикло [2.2.1] гептана | |
| US9777000B2 (en) | Pyrazole derivative | |
| JP2008513499A5 (enExample) | ||
| RU2011153772A (ru) | Фторированные аминотриазольные производные | |
| JP5345527B2 (ja) | プロドラッグである５−アミノ−３−（３’−デオキシ−β−Ｄ−リボフラノシル）−チアゾロ［４，５−ｄ］ピリミジン−２，７−ジオン | |
| JP2020512337A5 (enExample) | ||
| JP2014526500A5 (enExample) | ||
| CN1152870A (zh) | 杂环化合物作为多巴胺d3配位体的用途 | |
| JP2008513516A5 (enExample) | ||
| JP2015134783A (ja) | ５，６−ジヒドロ−１ｈ−ピリジン−２−オン化合物 | |
| JP2008516986A5 (enExample) | ||
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| JP2010536740A5 (enExample) | ||
| US8426405B2 (en) | Thiazopyrimidinones and uses thereof | |
| JP2020529998A5 (enExample) | ||
| JP2016532716A5 (enExample) | ||
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| RU2013130879A (ru) | Производные оксазолилметилового эфира в качестве агонистов рецептора alx | |
| RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| US11731985B2 (en) | Compositions and methods for treating cancer | |
| JP2006516626A5 (enExample) | ||
| RU2013125338A (ru) | Производные триазола в качестве лигандов рецепторов гамк |